Form 4: Teva Pharmaceutical Industries Executive Angus Grant Acquires 52,083 Restricted Share Units

EVP of Business Development at Teva Pharmaceutical Industries, Angus Grant, reports acquisition of 52,083 restricted share units on March 4, 2024.

Summary

• On March 4, 2024, Angus Grant, EVP of Business Development at Teva Pharmaceutical Industries, acquired 52,083 restricted share units.
• These units represent a contingent right to receive one ordinary share or the cash value of one ordinary share.
• The restricted share units vest in four tranches: 13,020 on each of March 4, 2025, March 4, 2026, and March 4, 2027, and 13,023 on March 4, 2028.
• Following the transaction, Grant beneficially owns 52,083 ordinary shares.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing indicating executive compensation. It doesn't inherently convey strong positive or negative sentiment, but the equity grant suggests confidence in the company's future.

Positives

• The acquisition of restricted share units by a key executive signals confidence in the company's future performance.

Future Outlook

The vesting schedule of the restricted share units suggests a long-term commitment by the executive to the company's success.

Industry Context

Executive compensation in the pharmaceutical industry often includes equity-based awards to align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock options and restricted stock units are common forms of executive compensation in the pharmaceutical industry, similar to practices at companies like Pfizer, Novartis, and Johnson & Johnson.
• Vesting schedules are typically structured to incentivize long-term performance, often over a 3-5 year period, which aligns with Teva's vesting schedule.

Stakeholder Impact

• The acquisition of restricted share units by an executive can positively influence shareholder sentiment.

Key Dates